Aclaris Therapeutics, Inc. (ACRS)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 3.3M | 1.3M | 2.0M | 1.6M |
| Gross Profit | 850K | (174K) | 208K | 176K |
| Operating Income | (17.0M) | (22.3M) | (22.2M) | (23.9M) |
| Net Income | (14.6M) | (19.8M) | (19.8M) | (21.5M) |
| Diluted EPS | $-0.12 | $-0.16 | $-0.15 | $-0.15 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 29.8M | 31.2M | 18.7M | 7.8M |
| Gross Profit | 17.8M | 13.2M | 3.3M | 542K |
| Operating Income | (85.2M) | (116.3M) | (52.5M) | (74.1M) |
| Net Income | (86.9M) | (88.5M) | (132.1M) | (64.9M) |
| Diluted EPS | $-1.33 | $-1.27 | $-1.71 | N/A |